Pharmacologic effects of ospemifene in rhesus macaques: A pilot study

Basic and Clinical Pharmacology and Toxicology

Volumn 102, Issue 6, 2008, Pages 552-558

  Wurz, Gregory T ^a   Hellmann Blumberg, Utha ^b   DeGregorio, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYOSPEMIFENE; CARBOXYOSPEMIFENE; DRUG METABOLITE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OSPEMIFENE; TRIACYLGLYCEROL;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA ADDUCT; DRUG ABSORPTION; DRUG EFFECT; DRUG HALF LIFE; DRUG RESEARCH; ENDOMETRIUM BIOPSY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER BIOPSY; MACACA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; LIPIDS; LIVER; MACACA MULATTA; PILOT PROJECTS; TAMOXIFEN; TOXICITY TESTS;

ANIMALIA; MACACA; MACACA MULATTA;

EID: 43749098542     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00235.x     Document Type: Article

References (26)

1. DeGregorio MW, Wurz GT, Taras TL, Erkkola RU, Halonen KH, Huupponen RK. Pharmacokinetics of (deaminohydroxy) toremifene in humans: a new, selective estrogen-receptor modulator. Eur J Clin Pharmacol 2000 56 : 469 75.
2. Komi J, Lankinen KS, DeGregorio M, Heikkinen J, Saarikoski S, Tuppurainen M et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 2006 24 : 314 18.
3. Komi J, Heikkinen J, Rutanen E-M, Halonen K, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 2004 18 : 152 8.
4. Ylikorkala O, Cacciatore B, Halonen K, Lassila R, Lammintausta R, Rutanen EM et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Menopause 2003 10 : 440 7.
5. Rutanen E-M, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 2003 10 : 433 9.
6. Qu Q, Zheng H, Dahllund J, Laine A, Cockcroft N, Peng Z et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000 141 : 809 20.
7. Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol 2001 77 : 271 9.
8. Namba R, Young LJT, Maglione JE, McGoldrick ET, Liu S, Wurz GT et al. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of DCIS. Breast Cancer Res 2005 7 : R881 9.
9. Wurz GT, Read KC, Marchisano-Karpman C, Gregg JP, Beckett LA, Yu Q et al. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol 2005 97 : 230 40.
10. Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002 43 : 207 214.
11. Komi J, Lankinen KS, Harkonen P, DeGregorio MW, Voipio S, Kivinen S et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause 2005 12 : 202 9.
12. Morello KC, Wurz GT, DeGregorio MW. SERMs: current status and future trends. Crit Rev Oncol Hematol 2002 43 : 63 76.
13. Glatt H, Davis W, Meinl W, Hermersdorfer H, Venitt S, Phillips DH. Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture. Carcinogenesis 1998 19 : 1709 13.
14. Phillips DH, Hewer A, Osborne MR, Cole KJ, Churchill C, Arlt VM. Organ specificity of DNA adduct formation by tamoxifen and α-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment. Mutagenesis 2005 20 : 297 303.
15. Hellmann-Blumberg U, Taras TL, Wurz GT, DeGregorio MW. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene. Breast Cancer Res Treat 2000 60 : 63 70.
16. Shibutani S, Ravindernath A, Terashima I, Suzuki N, Laxmi YR, Kanno Y et al. Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res 2001 61 : 3925 31.
17. Taras TL, Wurz GT, Hellmann-Blumberg U, DeGregorio MW. Quantitative analysis of Z-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl) phenoxy]ethanol in biological specimens using high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999 724 : 163 71.
18. Sambrook J, Fritsch EF, Maniatis T (eds). Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989.
19. Davies R, Oreffo VI, Martin EA, Festing MF, White IN, Smith LL et al. Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer Res 1997 57 : 1288 93.
20. Hellmann-Blumberg U, Cartner MG, Wurz GT, DeGregorio MW. Intrinsic reactivity of tamoxifen and toremifene metabolites with DNA. Breast Cancer Res Treat 1998 50 : 135 41.
21. Greendale GA, Judd HL. The menopause: health implications and clinical management. J Am Geriatr Soc 1993 41 : 426 36.
22. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997 314 : 228 31.
23. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000 61 : 3090 6.
24. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 288 : 321 33.
25. North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause 2007 14 : 168 82.
26. Doyle H. Effective topical treatments for atrophic vaginitis. JAAPA 2006 19 : 33 8.